Julien is a trained ophthalmologist, public health, and a data science for economics professional and spent his career at the intersection of global health, technology, and health equity working in the areas of maternal and child health, opioid use, HIV and hepatitis C treatment access.
He served as a head of health economics and policy for Oxfam GB, senior economist at the World Bank, chief of staff to Managing Partner at PricewaterhouseCoopers Public Sector, global technology strategy leader for health and life sciences industry at Accenture Cloud First. In his roles, he worked to support country health systems, including the United States, the United Kingdom, the Federal Republic of Germany, the Kingdom of Saudi Arabia, for efficient resource mobilization and allocation; assisted governments in the development of national health strategies including developing treatment access and country opioid response; participated in a multinational supply chain visibility program (for vaccines), and most recently, helped develop a technology and data strategy for cell and gene therapy supply chain.
Dr. Willard holds a doctorate degree from the Russian State Medical University, Master of Public Health and Economics from the London School of Hygiene and Tropical Medicine, and a diploma in international finance from the Yale University. He is a recipient of the World Bank President’s Award for Excellence (2017) and currently a visiting scholar at George Washington and Harvard Universities. Dr. Willard has served as the Oxfam’s liaison to G20 and to the United Nations in 2015 and currently represents the United States of America at the World Business Angels Investment Forum in the area of biotechnology and life sciences investments.
Dr. Julien Oleg Willard is a member of the American Society for Cell & Gene Therapy.
